Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
PubMed
31664740
PubMed Central
PMC7318267
DOI
10.1002/jmri.26948
Knihovny.cz E-resources
- MeSH
- Gadolinium MeSH
- Contrast Media * MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Cerebellar Nuclei MeSH
- Follow-Up Studies MeSH
- Organometallic Compounds * MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Gadolinium MeSH
- Contrast Media * MeSH
- Organometallic Compounds * MeSH
Department of Neurology Clinical Psychology Na Homolce Hospital Prague Czech Republic
Department of Radiology Na Homolce Hospital Prague Czech Republic
See more in PubMed
European Society of Urogenital Radiology (ESUR) guidelines on contrast agents, Version 10.0. [http://www.esur-cm.org/].
Kanda T, Fukusato T, Matsuda M, et al. Gadolinium‐based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–232. PubMed
European Medicines Agency: EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans. [https://www.ema.europa.eu/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents_en.pdf].
Gillies MJ, Hyam JA, Weiss AR, et al. The cognitive role of the globus pallidus interna: Insights from disease states. Exp Brain Res 2017;235:1455–1465. PubMed PMC
Payan CA, Viallet F, Landwehrmeyer BG, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: Validation of the NNIPPS—Parkinson Plus Scale. PLoS One 2011;6:e22293. PubMed PMC
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013;310:1842–1850. PubMed
Rulseh AM, Keller J, Klener J, et al. Long‐term survival of patients suffering from glioblastoma multiforme treated with tumor‐treating fields. World J Surg Oncol 2012;10:220. PubMed PMC
Welk B, McArthur E, Morrow SA, et al. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96–98. PubMed
Forslin Y, Shams S, Hashim F, et al. Retention of gadolinium‐based contrast agents in multiple sclerosis: Retrospective analysis of an 18‐year longitudinal study. AJNR Am J Neuroradiol 2017;38:1311–1316. PubMed PMC
Cocozza S, Pontillo G, Lanzillo R, et al. MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in multiple sclerosis. Neuroradiology 2019;61:155–162. PubMed
